Not Yet RecruitingPhase 2

Valbenazine in Obsessive Compulsive Disorder

30 participantsStarted 2026-05

Plain-language summary

The primary aim of the study is to examine the efficacy and safety of valbenazine in adults with moderate to severe obsessive-compulsive disorder (OCD).

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Men and women aged 18-65 years
✓. Primary diagnosis of obsessive compulsive disorder (OCD)
✓. Yale Brown Obsessive Compulsive Scale (Y-BOCS) score of at least 21 at baseline (moderate or higher severity)
✓. Ability to understand and sign the consent form

Exclusion criteria

✕. Unstable medical illness based on history or clinically significant abnormalities on baseline physical examination
✕. Current pregnancy or lactation, or inadequate contraception in women of childbearing potential
✕. Subjects considered an immediate suicide risk based on the Columbia Suicide Severity Rating Scale (C-SSRS) (www.cssrs.columbia.edu/docs)
✕. History of psychosis or bipolar disorder based on DSM-5 criteria
✕. Alcohol/substance use disorder and/or illegal substance use based on urine toxicology
✕. Initiation of psychological interventions within 3 months of screening (those who are continuing with CBT will be included)
✕. Use of any new psychotropic medication within 3 months of study entry (stable doses of psychotropics will be allowed)
✕. Major cognitive impairment that interferes with the capacity to understand and self-administer medication or provide written informed consent

What they're measuring

Yale-Brown Obsessive-Compulsive Scale (Y-BOCS)

Timeframe: Baseline to week 14

Trial details

NCT IDNCT07111988

SponsorUniversity of Chicago

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-12

Contact for this trial

Sophie Boutouis, BS

773-702-9066 sboutouis@bsd.uchicago.edu

View on ClinicalTrials.gov More Obsessive-Compulsive Disorder trials